ISR surveyed 296 decision-makers at sponsor organizations to evaluate the Phase II/III providers they have worked with in the past 18 months. Respondents were asked to assess the importance of 26 selection drivers to paint a picture of what is most important in their service provider selection process. Then, respondents evaluated service provider performance relative to their expectations along the same dimensions.
Based on this evaluation, Medpace was a top performer in the following categories:
- Overall: Top-5
- Customer Loyalty: Top 3
in 2017 and 3-year rolling average
- Organization Factors: Top 3
(Breadth of services, financial strength/stability, global footprint, operational excellence)
- Staff Characteristics: Top 2
(CRA quality, project manager quality, project team chemistry, responsiveness, staff turnover, study design expertise, therapeutic expertise, timely project communications)
Bold indicates attributes where Medpace was the only CRO to score “Clear Leadership.”
Read the ISR news release.
Medpace is a scientifically-driven, global full-service clinical research organization (CRO) providing Phase I-IV clinical development services for drug, biologic, and device programs. Medpace’s physician-led, high-science, and disciplined operating approach leverages regulatory and therapeutic expertise to accelerate the global development of safe and effective medical therapeutics across all major areas including hematology and oncology, cardiovascular, metabolic/diabetes, infectious diseases, and neurology and psychiatry.
About Industry Standard Research
Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about ISR’s off-the-shelf intelligence and custom research offerings, please visit the ISR website, email info@ISRreports.com, or follow ISR on Twitter @ISRreports.